Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2007 05:37 ET | Source: Jerini AG

Jerini Announces Research Collaboration Between Jerini Ophthalmic and UCL Institute of Ophthalmology Investigating New Treatments for AMD

BERLIN, Dec. 7, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that Jerini Ophthalmic, Inc., its wholly-owned U.S. subsidiary, signed a research collaboration agreement with...
November 14, 2007 03:18 ET | Source: Jerini AG

Jerini Reports Financial Results for First Nine Months of 2007

BERLIN, Nov. 14, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30,...
October 29, 2007 06:35 ET | Source: Jerini AG

Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review

BERLIN, Oct. 29, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the submission of its electronic New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE)...
October 09, 2007 03:11 ET | Source: Jerini AG

Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration

BERLIN, Oct. 9, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical...
October 08, 2007 04:45 ET | Source: Jerini AG

Jerini Initiates FDA Submission Process of New Drug Application For Icatibant in the Treatment of HAE

BERLIN, Oct. 8, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the complete New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been sent to...
September 04, 2007 07:40 ET | Source: Jerini AG

Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America

BERLIN, Sept. 4, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the termination of the license agreement between its affiliate, Jerini US, Inc., and Kos Life Sciences, Inc. for the...
August 16, 2007 09:23 ET | Source: Jerini AG

Jerini Receives EMEA Filing Acceptance of Its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema

BERLIN, Aug. 16, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the acceptance of its Marketing Authorization Application (MAA) by the European Medicines Evaluation Agency (EMEA) on...
August 14, 2007 03:13 ET | Source: Jerini AG

Jerini AG Reports First Half Financial Results for 2007

-- Submission of European Marketing Authorization Application completed -- Accelerated Assessment granted by EMEA for expedited review -- Completion of U.S. filing with FDA expected in third...
July 13, 2007 03:51 ET | Source: Jerini AG

FDA Accepts Jerini Ophthalmic's IND of JSM 6427 For the Treatment of AMD

BERLIN, July 13, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigative New Drug (IND) application submitted by...
May 15, 2007 03:22 ET | Source: Jerini AG

Jerini AG Reports First Quarter Financial Results

BERLIN, May 15, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2007. Under International Financial Reporting Standards (IFRS), revenues...